ArticleBritish journal of cancer2026
Hepatic metastasis surveillance in uveal melanoma: a retrospective cohort study from a UK tertiary centre (2006-2022).
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver surveillance imaging is essential for detecting early asymptomatic metastases in uveal melanoma, which predominantly involves the liver. Early detection may improve treatment opportunities, but variability in imaging protocols and a lack of consensus on surveillance duration present challenges. This study aimed to evaluate our systemic surveillance protocol, optimise pathways, and assess risk factors for metastasis.
methodsWe retrospectively analysed patients diagnosed with uveal melanoma between 2006 and 2021 who underwent hepatic imaging surveillance at Sheffield Teaching Hospitals NHS Foundation Trust. Demographics, tumour characteristics, treatments, disease status, and survival outcomes were collected.
resultsAmong 1086 patients (45% female, 79% White; median age 68 years), 315 (29%) developed metastases, with 293 (93%) detected within five years of ocular treatment. The number needed to scan (NNS) increased substantially after five years, indicating reduced detection efficiency. Higher T stage and ciliary body involvement were significantly associated with increased metastatic risk (P < 0.01).
conclusionsMost metastases from uveal melanoma occur within five years of treatment. Personalised, risk-based surveillance strategies considering tumour stage and location may improve efficiency and optimise healthcare resource use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.